The narrow promise of lecanemab for Alzheimer disease

CMAJ Podcasts by Canadian Medical Association Journal

Jul 27, 202634:28Science & Medicine

Lecanemab arrived in Canada in January 2026 as an anti-amyloid therapy meant to slow Alzheimer disease. A new practice article in CMAJ, "Lecanemab use for early Alzheimer disease in Canada," lays out key challenges with...

Related Episodes

Continue listening to more episodes from CMAJ Podcasts.

ENCORE: Rising psychosis, youth mental health, and what’s driving the trend

Sep 7, 2026 - 28:36

On this episode of the CMAJ Podcast, Dr. Mojola Omole and Dr. Blair Bigham explore new evidence suggestin...

ENCORE: Updated HIV prophylaxis guidelines: what clinicians need to know

Aug 24, 2026 - 36:52

Despite a range of effective prevention tools, HIV incidence continues to rise in Canada, with stark disp...

Emergency physician burnout and attrition

Aug 10, 2026 - 36:41

Emergency departments across Canada are seeing record patient volumes, bed shortages and overcrowding. A...

Rethinking the contrast allergy label

Jul 13, 2026 - 31:31

A contrast allergy note on the chart can trigger delays, unnecessary steroids and avoided scans, yet ofte...

Summer encore: Perspectives on the new guideline for managing obesity in children

Jun 29, 2026 - 31:21

It’s been nearly two decades since the last Canadian clinical practice guideline on managing obesity in c...

Relieving the symptoms and stigma of female urinary incontinence

Jun 15, 2026 - 27:50

Urinary incontinence affects about a third of adult women in Canada, yet many never receive a diagnosis o...

Understanding near-death experiences

Jun 1, 2026 - 29:28

Near-death experiences (NDE) are often described in spiritual, personal or even supernatural terms. But a...

Endometriosis and the devastating risks of untreated disease

May 18, 2026 - 33:12

Two articles in CMAJ look at endometriosis from sharply different angles. One shows how devastating delay...